Gentis news

On March 28, 2026, at Melia Hanoi Hotel, the Hanoi Society for Reproductive Support successfully organized the scientific workshop “Advances in Reproductive Medicine 13” with the main theme: “How to improve the success rate of IVF cycles”.

On March 28, 2026, at Melia Hanoi Hotel, the Hanoi Society for Reproductive Support will organize the scientific workshop “Advances in Reproductive Medicine 13” with the theme: “How to improve IVF cycle success rates.” This is one of the most important annual academic events in the field of reproductive support in Vietnam, attracting significant attention from doctors, scientists, embryologists, and healthcare managers in reproductive medicine.

In recent years, advancements in assisted reproductive technologies have provided the opportunity for millions of couples worldwide to become parents. However, beyond creating embryos through in vitro fertilization (IVF), selecting embryos with good genetic quality remains a crucial factor in achieving successful pregnancies. Numerous studies have shown that chromosomal abnormalities in embryos are among the common causes of implantation failure, early miscarriage, or genetic syndromes in children after birth. Therefore, preimplantation genetic testing (PGT) has become increasingly important in modern IVF procedures. To support fertility centers in optimizing embryo selection, Eurofins GENTIS has launched a new test, PGT-FAST – an embryo genetic screening solution with the outstanding advantage of delivering results in just 15 hours.

Recently, a delegation of experts from Eurofins GENTIS, led by Dr. Nguyen Quang Vinh (Director of Eurofins GENTIS Testing Center), held a professional working session with the doctors and nurses of the Hanoi General Hospital Assisted Reproduction Center. This collaboration aims to update the latest advances in genetic testing, thereby contributing to improved treatment outcomes for families facing infertility. The session also opened opportunities for academic exchange and laid the groundwork for deeper cooperation between the two units in the future.

Cancer is one of the leading causes of death worldwide. Numerous studies indicate that 5–10% of cancer cases are associated with hereditary factors, resulting from gene mutations that can be passed down from one generation to the next. Hereditary cancer testing helps identify risks early, enabling the development of appropriate monitoring, prevention, and medical intervention strategies.

Eurofins GENTIS solemnly hosted the Year End Party 2025 with the theme “United as One, Steadfast Forward.” The event was not only an occasion to review and reflect on a year of development, but also a meaningful space for connection, where the entire Eurofins GENTIS family gathered, shared, and spread the spirit of unity and determination toward the future.

In recent years, alongside in vitro fertilization (IVF), preimplantation genetic testing (PGT) solutions have increasingly been recognized as a key factor in improving success rates, minimizing risks, and working toward the goal of delivering healthy babies. Scientifically guided embryo selection plays a crucial role in helping clinicians and patients make safer and more effective decisions in each treatment cycle.